Compare OPK & BLFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPK | BLFS |
|---|---|---|
| Founded | 2007 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 1995 | 1989 |
| Metric | OPK | BLFS |
|---|---|---|
| Price | $1.30 | $24.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $2.28 | ★ $31.50 |
| AVG Volume (30 Days) | ★ 4.0M | 342.5K |
| Earning Date | 02-26-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $642,067,000.00 | $100,144,000.00 |
| Revenue This Year | N/A | $20.67 |
| Revenue Next Year | N/A | $14.13 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 87.53 |
| 52 Week Low | $1.11 | $19.10 |
| 52 Week High | $2.04 | $29.62 |
| Indicator | OPK | BLFS |
|---|---|---|
| Relative Strength Index (RSI) | 43.43 | 44.02 |
| Support Level | $1.24 | $23.28 |
| Resistance Level | $1.38 | $26.68 |
| Average True Range (ATR) | 0.05 | 0.96 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 37.04 | 29.46 |
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.